Pending ROW deal??, page-201

.
This is a discussion suggestion which is to allow shareholders to maximize the value of their various assets held within Neuren Pharma as it currently exists by splitting the company.
.
Multiple parts so as to separately reflect their various respective stages of development and underlying value.
.
Neuren Pharma Limited …. Retains cash+ income stream + Trofinitide North America (Arcadia) + Trofinetide for ROW (rest of world). Still in the ASX top 200..·
.
Son of Neuren (SON) ,,, NNZ 2591 for 4x indications + slab of shares in Neuren Pharma Limited.·
.
Daughter of Neuren (DON) … NNZ 2591 for everything else including Trofinetide for Traumatic Brain Injury and another slab of shares in Neuren Pharma Limited
.
Suggested mechanism is that all shareholders at date be each issued with· 2x shares in Neuren Pharma + 1 share in Son-of-Neuren (SON) + options sweetener + 1 share in Daughter-of-Neuren (DON) + options sweetener .
.
The existing cash and future cash flow from Trofinitide is able to flow from Neuren Pharma Limited into SON and DON via dividends and/or share placements.
.
This way the shareholders achieve maximum value for any and all parts. It could be also argued that smaller shareholders benefit from the options sweetener and thus a payback against being "financially flensed" via market manipulation a few months ago.
.
What do you think?
.